周宏灏院士集PDF电子书下载

第一部分 奋斗历程 1

中国遗传药理学的开拓者——记中国工程院院士周宏灏 3

第二部分 学术贡献 33

一、周宏灏院士的学术成就与学术思想 35

二、周宏灏院士的主要学术论文 42

Single-Dose Pharmacokinetics of Ceftriaxone in Healthy Chinese Adults 42

Racial Differences in Drug Response Altered Sensitivity to and Clearance of Propranolol in Men of Chinese Descent as Compared with American Whites 48

Interindividual Differences in β-receptor Density Contribute to Variability in Response toβ-adrenoceptor Antagonists 56

Induction of Polymorphic 4’-hydroxylation of S-mephenytoin by Rifampicin 60

Quinidine Reduces Clearance of（＋）-Propranolol More than（-）-Propranolol Through Marked Reduction in 4-Hydroxylation 64

Differences in Plasma Binding of Drugs Between Caucasians and Chinese Subjects 71

Increased Suppression of Exercise-Induced Increase in Renin by Propranolol in Chinese Subjects 78

Lack of Effect of Ageing on the Stereochemical Disposition of Propranolol 85

Differing Effect of Atropine on Heart Rate in Chinese and White Subjects 89

Ethnic Differences in Response to Morphine 94

Stereoselective Disposition of Carvedilol is Determined by CYP2D6 100

The Elimination of Diazepam in Chinese Subjects is Dependent on the Mephenytoin Oxidation Phenotype 107

In Vivo Inhibition of CYP2C19 But Not CYP2D6 by Fluvoxamine 112

Genetic Polymorphisms of Debrisoquine and S-mephenytoin Oxidation Metabolism in Chinese Populations：a Meta-analysis 116

Differences in the Incidence of the CYP2C19 Polymorphism Affecting the S-Mephenytoin Phenotype in Chinese Han and Bai Populations and Identification of a New Rare CYP2C19 Mutant Allele 121

Evidence for the Effect of Gender on Activity of（S）-Mephenytoin 4’-Hydroxylase （CYP2C19）in A Chinese Population 129

Meta-analysis of Phenotype and Genotype of NAT2 Deficiency in Chinese Populations 134

The Induction Effect of Rifampicin on Activity of Mephenytoin 4’-hydroxylase Related to M1 Mutation of CYP2C19 and Gene Dose 146

Evidence for Involvement of Polymorphic CYP2C19 and 2C9 in the N-demethylation of Sertraline in Human Liver Microsomes 149

Effect of the Gene Dosage of CYP2C 19 on Diazepam Metabolism in Chinese Subjects 157

Phenotypic Polymorphism and Gender-related Differences of CYP1A2 Activity in a Chinese Population 162

5-Hydroxylation of Omeprazole by Human Liver Microsomal Fractions from Chinese Populations Related to CYP2C19 Gene Dose and Individual Ethnicity 169

Ethnic Differences in Drug Metabolism 179

Effect of the CYP2C19 Oxidation Polymorphism on Fluoxetine Metabolism in Chinese Healthy Subjects 184

Pharmacokinetics of Sertraline in Relation to Genetic Polymorphism of CYP2C19 189

Plasma Caffeine Metabolite Ratio（17X/137X） in Vivo Associated with G-2964A and C734A Polymorphisms of Human CYP1A2 195

O-Dealkylation of Fluoxetine in Relation to CYP2C19 Gene Dose and Involvement of CYP3A4 in Human Liver Microsomes 202

Assessment of Cytochrome P450 Activity by a Five-drug Cocktail Approach 212

The Role of CYP2C19 in AmitriptylineN-demethylation in Chinese Subjects 219

Inducibility of CYP1A2 by Omeprazole in Vivo Related to the Genetic Polymorphism of CYP 1A2 225

Phenotypic Polymorphism of CYP2A6 Activity in a Chinese Population 229

Histamine N-methyltransferase Gene Polymorphisms in Chinese and Their Relationship with Enzyme Activity in Erythrocytes 235

Isozyme-specific Induction of Low-dose Aspirin on Cytochrome P450 in Healthy Subjects 246

Gly389Arg Polymorphism of β1-adrenergic Receptor is Associated with the Cardiovascular Response to Metoprolol 254

Pharmacokinetics of Citalopram in Relation to Genetic Polymorphism of CYP2C19 261

The Distribution and Gender Difference of CYP3A Activity in Chinese Subjects 268

St John’s Wort Induces Both Cytochrome P450 3A4-catalyzed Sulfoxidation and 2C19-dependent Hydroxylation of Omeprazole 274

Iiell8Val Genetic Polymorphism of CYP3A4 and Its Effects on Lipid-lowering Efficacy of Simvastatin in Chinese Hyperlipidemic Patients 281

Gender Specific Association of CYP2C9*3 with Hyperlipidaemia in Chinese 288

β1-Adrenergic Receptor Polymorphisms Influence the Response to Metoprolol Monotherapy in Patients with Essential Hypertension 291

Effect of SLCO1B1 Genetic Polymorphism on the Pharmacokinetics of Nateglinide 301

Frequency of Genetic Polymorphisms of COX 1，GP Ⅲ a and P 2Y1 in a Chinese Population and Association with Attenuated Response to Aspirin 307

SLCO1B1 521T→C Functional Genetic Polymorphism and Lipid-lowering Efficacy of Multiple-dose Pravastatin in Chinese Coronary Heart Disease Patients 316

The Effect of Herbal Medicine Baicalin on Pharmacokinetics of Rosuvastatin，Substrate of Organic Anion-transporting Polypeptide 1B1 322

Hepatic Nuclear Factor 1α Inhibitor Ursodeoxycholic Acid Influences Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 Substrate Rosuvastatin and Bilirubin 329

Effects of Ginkgo Biloba Extract on the Pharmacokinetics of Bupropion in Healthy Volunteers 334

Plant Polyphenol Curcumin Significantly Affects CYP1A2 and CYP2A6 Activity in Healthy，Male Chinese Volunteers 340

Pharmacogenetics of Drugs Withdrawn from the Market 349

三、周宏灏院士的主要学术著作 358

药理学 358

Textbook of Pharmacology 360

Case Files TM Pharmacology 363

Pharmacology 365

遗传药理学（第2版） 368

四、周宏灏院士重要学术报告、重要讲话 369

Ethnic Differences in Drug Response 369

Pharmacogenetic Research about Natural Medicine Effect of Natural Medicine on CYP450 370

Ethnic Differences in Drug Metabolism 372

Genetic Polymorphism of CYP2C19 in Chinese Populations 373

Pharmacogenetics and Pharmacogenomics in Asian Populations and Impact on Clinical Pharmacology 374

Racial Differences in Drug Response Reflect Differences in Distribution of Polymorphic Traits 375

Pharmacogenetic and Pharmacogenomic Research in China 376

Ethnicity，Genetics and Tailored Pharmacotherapy 377

个体化药物治疗的研究与开发 378

药物基因组学研究技术成果在药物临床评价中的应用 379

在临床试验中不能忽视亚洲人群种族差异的基因多态性 381

药物代谢酶基因多态性与个体化药物治疗 382

个体化医学的实施与展望 383

五、周宏灏院士学术年表 384

周宏灏院士论文目录 384

周宏灏院士专著目录 424

周宏灏院士科研与教学成果目录 425

周宏灏院士获国家发明专利目录 427

第三部分 治学之道 429

勤勉严谨做学问 情系祖国育桃李 431

遗传药理学研究的先行者 435

善于发现 勇于挑战——访临床药理学家周宏灏院士 439

中国遗传药理学开拓者周宏灏：立志如山 行道如水 445

周宏灏：中国个体化用药的“拓荒者” 449

让患者用药更精确 454

用药也需“量体裁衣”——访我国著名遗传药理学家周宏灏教授 456

第四部分 大师风范 461

一、感悟、经验与情怀 463

做人 做事 做学问 463

心系学子 桃李芬芳 以德服人 从严治学 465

医学教育不能硬套综合大学管理体制——中国工程院院士周宏灏谈我国医学教育现状与改革 467

春蚕到死丝方尽，人至期颐亦不休 470

我的情操 472

二、部分学生的代表性论文 475

Effect of Asymmetric Dimethylarginine on Osteoblastic Differentiation 475

Effect of SLCO1B1 Genetic Polymorphism on the Pharmacokinetics of Nateglinide 476

Evidence for Involvement of Calcitonin Gene-Related Peptide in Nitroglycerin Response and Association with Mitochondrial Aldehyde Dehydrogenase-2 （ALDH2） Glu504Lys Polymorphism 477

Molecular Population Genetics of Human CYP3A Locus：Signatures of Positive Selection and Implications for Evolutionary Environmental Medicine 478

Coupling HPLC to on-line，Post-column（bio） Chemical Assays for High-resolution Screening of Bioactive Compounds from Complex Mixtures 479

KCNJ 11 Lys23Glu and TCF7L2 rs290487（C/T） Polymorphisms affect Therapeutic Efficacy of Repaglinide in Chinese Patients with Type 2 Diabetes 480

Inhibition of the Organic Anion-transporting Polypeptide 1B1 by Quercetin：An in Vitro and in Vivo Assessment 481

Effect of eIF3a on Response of Lung Cancer Patients to Platinum-Based Chemotherapy by Regulating DNA Repair 482

The Pregnane X Receptor Agonist St John’s Wort Has No Effects on the Pharmacokinetics and Pharmacodynamics of Repaglinide 483

Effects of Lignans Extracted from Eucommia Ulmoides and Aldose Reductase Inhibitor Epalrestat on Hypertensive Vascular Remodeling 484

ABCC2 Polymorphisms and Haplotype are Associated with Drug Resistance in Chinese Epileptic Patients 485

Theragnostics Meets Traditional Chinese Medicine：Rational Prediction of Drug-herb Interactions 486

Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer（NSCLC） Patients 487

Protective Effects of Eucommia Lignans Against Hypertensive Renal Injury by Inhibiting Expression of Aldose Reductase 488

Translational Regulation of RPA2 Via Internal Ribosomal Entry Site and by eIF3a 489

Effect of NR3C2 Genetic Polymorphisms on the Blood Pressure Response to Enalapril Treatment 490

The KCNH2 Genetic Polymorphism（1956，C＞T） Is a Novel Biomarker That Is Associated with CCB and α，β-ADR Blocker Response in EH Patients in China 491

Polymorphism of ORM1 Is Associated with the Pharmacokinetics of Telmisartan 492

Current Pharmacogenomic Studies on hERG Potassium Channels 493

Deficiency of Multidrug and Toxin Extrusion 1 Enhances Renal Accumulation of Paraquat and Deteriorates Kidney Injury in Mice 494

Effects of the Peroxisome Proliferator Activated Receptor-γ Coactivator-lα（PGC-1α） Thr394Thr and Gly482Ser Polymorphisms on Rosiglitazone Response in Chinese Patients with Type 2 Diabetes Mellitus 495

Characterization and Analyses of Multidrug Resistance-associated Protein 1 （MRP1/ABCC 1）Polymorphisms in Chinese Population 496

第五部分 社会影响 497

我学者首次发现不同种族对药物的差异性 499

Effectiveness of Drugs May be Influenced by Racial and Ethnic History 500

深入了解中国人的心脏 502

种族与药物的治疗效应 503

β-受体阻滞药效应呈现种族差异 505

药物效应的种族差异 507

我国医学科技占世界之首成果巡礼 509

Biomedicine 510

DNA Chips Bring Personalized Medicine to China 512

开拓国际临床药理新领域——记中国工程院院士周宏灏 515

世界首张个体化用药基因芯片初步研制成功 521

个体化用药成为焦点 522

用多少药，问问你的遗传基因 523

基因芯片：有助于药物治疗个体化 524

用药也可“量体裁衣” 525

周宏灏教授当选世界药理学联合会药物代谢学会理事 526

省儿童医院聘请周宏灏为终身首席科学家 527

引领人类个体化用药新时代的人——记我国著名临床与遗传药理学家周宏灏教授 528

研发一体化做强湖南医药产业——访中国遗传药理学专家、中南大学临床药理研究所所长、中国工程院院士周宏灏教授 538

种族差异、遗传及个体化药物治疗 542

第六部分 人生风采 543

成长历程 545

教书育人 547

学术交流 550

珍贵合影 553

人文情怀 555